TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7964541
Drug: Alpha-galactosidase solution
Normalized name: ALPHA-GALACTOSIDASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-galactosidase solution (8 drops)
Study: 3058656
Drug: Prostatic bed
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostatic bed irradiation only (6500 cGy at 180‐200 cGy per treatment)
Study: 3058656
Drug: Pelvic node
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic node irradiation to 4500 cGy with a boost of 2000 cGy to the prostatic bed (total dose 6500 cGy)
Study: 25611899
Drug: Nonpegylated doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpegylated doxorubicin citrate (60 mg/m) and carboplatin (AUC 5) every 3 weeks for 6 to 9 cycles
Study: 21516059
Drug: Levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium soft capsule formulation (Tirosint)
Study: 21516059
Drug: 50-, 100-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-, 100-, and 150-μg test capsules strengths dosed at 600 μg
Study: 21516059
Drug: New capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: New capsule formulation following the new potency guideline (±5%)
Study: 16601647
Drug: Paroxetine (10-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (10-50 mg/day)
Study: 1305891
Drug: Interferon alfa‐n3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐n3 (Alferon N Injection)
Study: 2867653
Drug: etintidine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: etintidine 300 mg
Study: 2867653
Drug: etintidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: etintidine 600 mg
Study: 25209306
Drug: Living in
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living in a couple with a non-drug user
Study: 25209306
Drug: Living in
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living in a couple with a drug user
Study: 19317607
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg weekly
Study: 21989542
Drug: Etanercept (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (both doses)
Study: 20979784
Drug: rhPTH (1‐34)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH (1‐34) 20 µg daily
Study: 16093464
Drug: Alendronate after
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate after parathyroid hormone (1-84) therapy
Study: 16093464
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after parathyroid hormone (1-84) therapy
Study: 12501881
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg administered on the last day of the OC regimen
Study: 12501881
Drug: Norethindrone 1
Normalized name: norethindrone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone 1 mg/ethinyl estradiol 0.035 mg (NE/EE)
Study: 1645384
Drug: SDZ 89‐104,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ 89‐104, 2 mg/kg
Study: 1645384
Drug: SDZ 89‐109,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ 89‐109, 2 mg/kg
Study: 1645384
Drug: SDZ 89‐104,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ 89‐104, 0.5 mg/kg
Study: 1645384
Drug: SDZ 89‐109,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ 89‐109, 0.5 mg/kg
Study: 1645384
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum levels (2 mg/kg)
Study: 28738008
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao (15 mg/kg)
Study: 25941765
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (300 mg per day for 20 days)
Study: 25941765
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (300 mg per day for 20 days)
Study: 24885672
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine (Salbutamol, Formoterol, Salmeterol/fluticasone)
Study: 24885672
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatments (Bufei granule, Bu‐Fei Jian‐Pi granule, Bu‐Fei Yi‐Shen granule, Yi‐Qi Zi‐Shen granule)
Study: 24885672
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conventional Western medicine and TCM treatments
Study: 16923461
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg loading dose
Study: 21685174
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose
Study: 17445432
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (300 mg and 600 mg)
Study: 14709457
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 10 mg.kg(‐1) bolus before surgery plus a 1 mg.kg(‐1).hr(‐1) infusion until wound closure (Group TA)
Study: 9737091
Drug: meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 7.5 mg/d for 6 days
Study: 9737091
Drug: indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 25 mg tid for 2 days and 25 mg on the 3rd day
Study: 7995320
Drug: Nonfiltered 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfiltered 0 mg nicotine cigarette
Study: 7995320
Drug: Low (0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low (0.27 mg) nicotine cigarette
Study: 7995320
Drug: High (2.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: High (2.16 mg) nicotine cigarette
Study: 2843029
Drug: Oat and
Normalized name: Oat and wheat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat and bean products as dietary supplements
Study: 29966645
Drug: Interactive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive group treatment (13 weekly sessions, 1.5 hours each) with structured and facilitated group interactions
Study: 29966645
Drug: Noninteractive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninteractive treatment (13 traditional classroom sessions with brief supplemental individual sessions)
Study: 26867200
Drug: DHA as
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA as part of a multinutrient supplement (including Gingko biloba, phosphatidylserine, vitamins B₉ and B₁₂)
Study: 18702660
Drug: EC‐MPS (1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS (1080 mg bid)
Study: 18702660
Drug: MMF (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (1500 mg bid)
Study: 16880774
Drug: GHB (2‐18
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (2‐18 g/70 kg)
Study: 16880774
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 and 1 mg/70 kg)
Study: 16880774
Drug: Pentobarbital (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (200 and 400 mg/70 kg)
Study: 8380634
Drug: Cisplatin (CDDP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Vindesine (VDS; 3 mg/m2 on days 1 and 8)
Study: 8380634
Drug: Cisplatin (CDDP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Mitomycin C (MMC; 8 mg/m2 on days 1 and 8)
Study: 30236087
Drug: Dacryocystorhinostomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacryocystorhinostomy with Silicone tubes and Ologen implants (Group B)
Study: 15735611
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice 300 mL
Study: 15735611
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice 1200 mL
Study: 12824095
Drug: Ex‐warfarin users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex‐warfarin users
Study: 8856481
Drug: LRB081 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRB081 10 mg
Study: 8856481
Drug: LRB081 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRB081 40 mg
Study: 8856481
Drug: LRB081 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: LRB081 80 mg
Study: 1732347
Drug: Urokinase (4,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (4,400 U/kg as an intravenous bolus infusion, then 4,400 U/kg per h over 12 h; n = 29)
Study: 1732347
Drug: Alteplase (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (10 mg as an intravenous bolus infusion, then 90 mg over 2 h; n = 34)
Study: 12416659
Drug: IBI/S (silybin-beta-cyclodextrin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI/S (silybin-beta-cyclodextrin) 135 mg/d
Study: 8595515
Drug: Double combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double combination therapy
Study: 792404
Drug: Estolate suspension
Normalized name: meadowfoam estolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estolate suspension
Study: 792404
Drug: Ethyl succinate
Normalized name: Dimethyl succinate
DrugBank: Triethyl phosphate (DB03347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl succinate suspension
Study: 28557589
Drug: Ophthalmic viscosurgical
Normalized name: Viscoat Ophthalmic Viscosurgical Device Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic viscosurgical device
Study: 23352760
Drug: Morphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine treatment (10 μg/kg/h during the neonatal period)
Study: 10398579
Drug: ThinPrep preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThinPrep preparations
Study: 22543884
Drug: Total radiation
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total radiation dose
Study: 1854047
Drug: Etomidate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.5 mg.kg‐1)
Study: 31701432
Drug: No recall
Approvals — FDA: no, EMA: no, PMDA: no
Description: No recall period (standard PROMIS administration)
Study: 17906192
Drug: EGCG (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (300 mg/d for 2 days)
Study: 16140426
Drug: 2 cans/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cans/day of a protein and energy dense oral nutrition supplement +/− n-3 fatty acids
Study: 2138489
Drug: Doxacurium (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxacurium (initial dose of 25 micrograms kg‐1, with incremental doses of 5 micrograms kg‐1)
Study: 2138489
Drug: Neostigmine (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.08 mg kg‐1)
Study: 2138489
Drug: Edrophonium (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (1.0 mg kg‐1)
Study: 30082073
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg daily
Study: 16401736
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg daily
Study: 24885673
Drug: Dader Method
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dader Method of pharmaceutical care
Study: 21418281
Drug: Topical 3%
Normalized name: sulfur topical 3% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 3% diclofenac sodium plus hyaluronan (DFS) gel, twice daily for 12 weeks
Study: 21418281
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod (IMQ) cream, twice per week for 16 weeks
Study: 21418281
Drug: Base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base cream (BC), twice daily for 12 weeks
Study: 15643103
Drug: Gepirone ER
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone ER (20 mg/d titrated to 40 to 80 mg/d)
Study: 12224305
Drug: Immunosuppressive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive agents and 99Tc-MDP
Study: 10428516
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injections of 0.1 mL sterile water
Study: 10428516
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of 0.5 mL sterile water
Study: 1969982
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion at progressively increased concentrations
Study: 17321923
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 10 mg of hyperbaric 1% lidocaine (L group, n=40)
Study: 17321923
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with fentanyl 1 microg.kg‐1 IV and 1.0 mg.kg‐1 propofol (F/P group, n=40)
Study: 15646652
Drug: Ferrous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous iron supplement (Ferall, a combination of ferrous fumarate with ascorbic acid, folic acid, and cyanocobalamin)
Study: 3139571
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 250 mg mixed testosterone esters at 2-week intervals
Study: 3139571
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate 120 mg bd
Study: 3139571
Drug: Subcutaneous testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous testosterone pellets (6 x 100 mg)
Study: 26214071
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with GBNs (13 g/day for three months)
Study: 23356951
Drug: Virtual reality‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality‐based vocational training group (VRG) and therapist‐administered group (TAG)
Study: 16958945
Drug: SSRI‐assisted BDZ‐reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI‐assisted BDZ‐reduction group (10‐20 mg of paroxetine, n = 22)
Study: 15534491
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine given daily for 4 days
Study: 11464354
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg of intraarticular clonidine with subcutaneous saline
Study: 11464354
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg of intraarticular neostigmine with subcutaneous saline
Study: 11464354
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg of intraarticular clonidine and 500 microg of neostigmine with subcutaneous saline
Study: 11464354
Drug: 150 microg
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg of intraarticular clonidine with 500 microg of subcutaneous neostigmine
Study: 11464354
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg of intraarticular neostigmine with 150 microg of subcutaneous clonidine
Study: 11464354
Drug: intraarticular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarticular and subcutaneous isotonic saline
Study: 7893580
Drug: Didanosine 100
Normalized name: didanosine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 100 mg
Study: 3556193
Drug: Slow-release oxprenolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oxprenolol 160 mg
Study: 3556193
Drug: Slow-release oxprenolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oxprenolol 320 mg
Study: 3556193
Drug: Oros oxprenolol
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oros oxprenolol 10/170 mg
Study: 24363363
Drug: Amoxicillin dissolved
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin dissolved in human milk at a concentration of 50 mg/mL
Study: 24363363
Drug: Amoxicillin dissolved
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin dissolved in water at a concentration of 50 mg/mL
Study: 20035226
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg kg(‐1)
Study: 20035226
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg kg(‐1) + low-dose oral ketamine 2 mg kg(‐1)
Study: 2707399
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (both groups)
Study: 17642108
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lithium chloride (0.72 mEq/kg/day)
Study: 17642108
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose lithium chloride (0.5 mEq/kg/day)
Study: 17642108
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lithium chloride (0.24 mEq/kg/day)
Study: 28526329
Drug: Sham intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham intervention consisting of weekly phone calls for 6 weeks.
Study: 22554598
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg prasugrel
Study: 21784373
Drug: Extended-release niacin/laropiprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin/laropiprant (1g niacin/20 mg laropiprant) for the first 4 weeks, then 2 tablets once daily thereafter
Study: 17225939
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (6.0 Gy total, 1.0 Gy per fraction, 2 fractions per week for 3 weeks)
Study: 17225939
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (3.0 Gy total, 0.5 Gy per fraction, 2 fractions per week)
Study: 30005744
Drug: Midodrine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (2.5 mg twice a day)
Study: 30005744
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg twice a day)
Study: 30005744
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of midodrine and pyridostigmine
Study: 25007091
Drug: pSG2.HIVconsv DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pSG2.HIVconsv DNA vaccine
Study: 25007091
Drug: ChAdV63.HIVconsv vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdV63.HIVconsv vaccine
Study: 25007091
Drug: MVA.HIVconsv vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA.HIVconsv vaccine
Study: 19931416
Drug: IRSCE at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRSCE at 14.0 g (7.8 g of inulin)
Study: 19931416
Drug: IRSCE at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRSCE at 8.1 g/d (5.0 g of inulin)
Study: 19931416
Drug: Control (sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sucrose 10 g and 8.1 g/d)
Study: 10720834
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate
Study: 11494545
Drug: IFN-ribavirin combination
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IFN-ribavirin combination therapy
Study: 11494545
Drug: IFN monotherapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN monotherapy
Study: 9470077
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (SB) 400 micrograms every 4 hours
Study: 9470077
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (SM) 100 micrograms every 12 hours
Study: 31361019
Drug: NKTR-181 (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 (100-600 mg BID)
Study: 28784179
Drug: Social skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social skills training (n=10 CCS), bi-weekly sessions over 8 months covering making social contacts, problem solving, emotional self-regulation, emotional expression and recognition.
Study: 25488448
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficient (<12 ng/ml)
Study: 25488448
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficient (12 to <20 ng/ml)
Study: 25488448
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficient (≥ 20 ng/ml)
Study: 19323613
Drug: Cyclobenzaprine ER
Normalized name: cyclobenzaprine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine ER 30 mg
Study: 19323613
Drug: Cyclobenzaprine ER
Normalized name: cyclobenzaprine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine ER 15 mg
Study: 19323613
Drug: Cyclobenzaprine immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine immediate release (CIR) 10 mg
Study: 11304861
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of estriol (1 mg/d) and pelvic floor muscle exercise (PFME)
Study: 3115138
Drug: Intrathecal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal buprenorphine (0.15 mg) plus 20 mg tetracaine